Sinogen Pharmaceutical's investigational new drug has been selected for the service list of key drug varieties in the Greater Bay Area

On July 10, 2024, Guangzhou Sinogen Pharmaceutical received a notice from the Greater Bay Area Drug Evaluation and Inspection Center of the National Medical Products Administration, stating that oncolytic bacteria SGN1 injection ( SalMet-Vec^®) was selected for the key variety service list of the Greater Bay Area Center for Drugs.

The list of key projects of the Greater Bay Area Center for Drugs is a service variety list developed for drugs under development (including early development), focusing on clinical value and encouraging original innovation. This measure is based on the "Work Plan for Supporting and Serving Key Projects of Drug Innovation and Research in the Greater Bay Area" formulated by the National Medical Products Administration in conjunction with the Greater Bay Area Center for Drugs, and has been reviewed and approved for implementation by the National Medical Products Administration.

Applicants included in the list of key varieties can submit applications for communication guidance, filing guidance, etc. based on the communication needs of each research and development stage, in accordance with the current work procedures of the sub center. The sub center will receive and set up separate service sequences, priority arrangements, and dedicated personnel services.